If you are going to post UK measurements in a forum with mostly US based members you have got to include lab ranges because most are not familiar with UK lab ranges where Labcorp is king and is the 800 pound gorilla.
Your SHBG is way over the reference ranges and began negatively affecting your Free T in the mid 40’s, I must assume Free T is very low. TRT doesn’t cause prostate cancer and I repost all studies here for you to look at since I can’t post links.
There area lot of seriously flawed studies out there about how TRT causes cancer, heart disease and cardiovascular disease and yet all other studies are showing the opposite, we know low testosterone causes all of these disease and it’s ludicrous to believe that healthy testosterone levels in the high normal ranges does anything other than make you healthy.
You need TRT bro, excess androgen is probably the only thing that will lower SHBG enough to increase Free T. You need to go private as knowledge is severely lacking in state healthcare systems. Balance my hormones is in Dorset and believe it’s a telemedicine clinic where they can send you a blood testing kit. You won’t find anyone here on T-Gels, they rarely get men in the therapeutic optimal ranges.
140-160mg enanthate once weekly or split either of those doses up twice weekly. Sustanon once weekly is a second option, enanthate should be prefered and Nebido avoided! Injections you don’t have to worry about absorption issues, injections is 100 percent absorbed where gels are generally poorly absorbed through the skin.
The use of testosterone therapy in men with prostate cancer was previously contraindicated, although recent data challenge this axiom. Over the past 2 decades, there has been a dramatic paradigm shift in beliefs, attitude, and treatment of testosterone deficiency in men with prostate cancer.
To summarize and analyze current literature regarding the effect of testosterone replacement in men with prostate cancer.
We conducted a Medline search to identify all publications related to testosterone therapy in both treated and untreated prostate cancer.
The historical notion that increasing testosterone was responsible for prostate cancer growth was based on elegant yet limited studies from the 1940s and anecdotal case reports. Current evidence reveals that high endogenous androgen levels do not increase the risk of a prostate cancer diagnosis. Similarly, testosterone therapy in men with testosterone deficiency does not appear to increase prostate cancer risk or the likelihood of a more aggressive disease at prostate cancer diagnosis. Androgen receptor saturation (the saturation model) appears to account for this phenomenon. Men who received testosterone therapy after treatment for localized prostate cancer do not appear to suffer higher rates of recurrence or worse outcomes; although studies to date are limited. Early reports of men on active surveillance/watchful waiting treated with testosterone have not identified adverse progression events.
An improved understanding of the negative effects of testosterone deficiency on health and health-related quality of life—and the ability of testosterone therapy to mitigate these effects—has triggered a re-evaluation of the role testosterone plays in prostate cancer. An important paradigm shift has occurred within the field, in which testosterone therapy may now be regarded as a viable option for selected men with prostate cancer suffering from testosterone deficiency.